Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Biocon

What Is The Impact Of Rupee Appreciation On Pharma & InfoTech Stocks & Should We Buy Them? Daljeet Kohli



The appreciation in the value of the INR vis-à-vis the USD has caused Pharma & InfoTech stocks to under-perform the Index. Daljeet Kohli explains the extent of the impact and offers valuable advice on what investors should do

Did You Know That Mutual Funds Are Giving 45+% Annual Gain?



It is astonishing that several diversified small-cap and mid-cap mutual funds have given incredible annual returns of upto 48%. How have they achieved this feat?

Time To Take Your Money Off The Table And Run: Ashwani Gujral



Ashwani Gujral has given sensible advice that investors should take advantage of the rally to book some profits and park it for deployment when the market crashes

Ashwani Gujral’s Top Mid-Cap Stock Picks For 2014



Ashwani Gujral is a veteran stock trader who has a number of good stock calls to his credit. He says that Mid-caps are coming out of a bear phase and the time is ripe to buy them. He reveals his top stock picks for 2014

Top 10 Mid-cap Stock Ideas From IIFL For 2014



IIFL has released a report in which it has identified stocks with good fundamentals and reasonable valuations which are expected to do well in the medium to long-term

Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 509 other subscribers

RSS Stocks Talk Forum

  • Raymond Lifestyle has multiple growth drivers. Target Price ₹3000 (+49%)
    Raymond Lifestyle has multiple growth drivers. It boasts legacy of established brands such as Park Avenue. However brands remain under-penetrated due to sluggish execution in past. Renewed focus on growth could lead to valuation re-rating. TP ₹3000 (+49%) Download research report... Raymond Lifestyle has multiple growth drivers. Target Price ₹3000 (+49%)
  • Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr
    Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr. M-Cap is ₹5800 Cr. Promoters hold 46%. Co operates in 3 areas i.e. Xanthine derivatives, API & CDMO/CMO. It is largest Indian manufacturer of Xanthines & has Global market share of 15-20% ... Sunil Singhania's Abakkus has bought 10.69L shares […]
  • PNB Housing is undergoing a transformation to morph into a franchise that will be stronger
    PNB Housing is undergoing a transformation to morph into a franchise that will be stronger, more resilient & with high predictability in earnings trajectory. Risk-reward profile is favorable for a long-term investor. Buy for TP of ₹1160 (38% upside) Download research... PNB Housing is undergoing a transformation to morph into a franchise that will be […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!